On Heels of $17 Billion SPAC Deal, Ginkgo Inks Collab with Synthetic Biology Firm

California synthetic biology firm Antheia has joined forces with Boston-based biotech company Ginkgo Bioworks to strengthen its efforts to develop and produce essential medicines to treat a wide range of diseases.

Antheia is looking to leverage Ginkgo's cell programming technology and high throughput enzyme design and screening capabilities to support its pipeline of critical active pharmaceutical ingredients (APIs) and key starting materials (KSMs).


Read the article at BioSpace

0 comments